论文部分内容阅读
Approved and investigational therapeutic monoclonal antibodies (mAbs) represent the leading sector of the biopharmaceuticals market and research.However, pursuing mAb affinity and structural similarity to human immunoglobulin (Ig) has a great impact on the integrity of the pairing between heavy and light chains, making them sometimes immunogenic to patients and thus ineffective therapeutic agents.Our study is aimed to develop a platform for therapeutic mAbs using human lymphocytes derived from healthy donors to further maximize possible clinical application and efficacy involved.High affinity complete human IgGs to given epitopes were induced by synthetic peptides encompassing a part of antigen in cultured human lymphocytes.